Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-21-020263

Chief Financial Officer gave up 1,352 shares (to pay taxes)

  • Chief Financial Officer acquired 2,833 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
TOMSICEK MICHAEL JOHN Chief Financial Officer 2021-03-10 Option exercise +2,833 3,243 D
TOMSICEK MICHAEL JOHN Chief Financial Officer 2021-03-10 Shares withheld for taxes −1,352 $124.15 $167,851 1,891 D
Derivatives
TOMSICEK MICHAEL JOHN Chief Financial Officer 2021-03-11 Grant or award · Stock Option (Right to Buy) +25,360 25,360 D
TOMSICEK MICHAEL JOHN Chief Financial Officer 2021-03-11 Grant or award · Restricted Stock Units +9,000 9,000 D
Loading xslF345X03/doc4.xml…